Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer

Purpose of Review The field of liquid biopsies is constantly evolving through novel technologies. This review outlines current data on liquid biopsies and application to clinical management of metastatic prostate cancer. Recent Findings To date, there are three platforms with FDA approval for use in the setting of metastatic prostate cancer and others which have been clinically validated. There is substantial evidence supporting the use of circulating tumor cell (CTC) enumeration to guide prognosis in metastatic castration-resistant prostate cancer (mCRPC). Additional evidence supports targeted sequencing of CTC and cell-free DNA (cfDNA) to guide androgren-directed therapy, identify candidates for treatment with PARP inhibitors, and monitor development of resistance. As a real-time and minimally invasive approach, utilization of liquid biopsies has the potential to drastically impact the treatment of metastatic prostate cancer and improve overall survival. With further clinical validation, additional liquid biopsy is likely to enter standard clinical practice.

Automated summary

This review outlines current data on liquid biopsies and their application in the clinical management of metastatic prostate cancer. Research findings suggest that liquid biopsies have significant potential in guiding prognosis, treatment selection, and resistance monitoring in metastatic prostate cancer. Further validation is needed to incorporate liquid biopsies into standard clinical practice.